A detailed history of Ubs Group Ag transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 307 shares of PLX stock, worth $322. This represents 0.0% of its overall portfolio holdings.

Number of Shares
307
Previous 67,956 99.55%
Holding current value
$322
Previous $85,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$1.1 - $1.32 $74,413 - $89,296
-67,649 Reduced 99.55%
307 $0
Q1 2024

May 13, 2024

SELL
$1.22 - $1.82 $8,249 - $12,306
-6,762 Reduced 9.05%
67,956 $85,000
Q4 2023

Feb 09, 2024

BUY
$1.34 - $1.85 $50,461 - $69,667
37,658 Added 101.61%
74,718 $132,000
Q3 2023

Nov 09, 2023

SELL
$1.49 - $2.02 $22,320 - $30,259
-14,980 Reduced 28.79%
37,060 $61,000
Q2 2023

Aug 11, 2023

BUY
$2.0 - $3.36 $94,698 - $159,092
47,349 Added 1009.36%
52,040 $104,000
Q1 2023

May 12, 2023

BUY
$1.37 - $2.16 $6,262 - $9,873
4,571 Added 3809.17%
4,691 $9,000
Q4 2022

Feb 08, 2023

SELL
$1.0 - $1.37 $10,998 - $15,067
-10,998 Reduced 98.92%
120 $0
Q3 2022

Nov 10, 2022

BUY
$1.03 - $1.24 $11,327 - $13,637
10,998 Added 9165.0%
11,118 $11,000
Q4 2021

Feb 14, 2022

SELL
$0.81 - $1.33 $1,777 - $2,918
-2,194 Reduced 94.81%
120 $0
Q3 2021

Nov 15, 2021

BUY
$1.31 - $1.87 $509 - $727
389 Added 20.21%
2,314 $3,000
Q2 2021

Aug 13, 2021

SELL
$1.86 - $6.22 $502 - $1,679
-270 Reduced 12.3%
1,925 $3,000
Q1 2021

May 12, 2021

BUY
$3.58 - $6.45 $3,572 - $6,437
998 Added 83.38%
2,195 $10,000
Q4 2020

Feb 11, 2021

SELL
$3.15 - $3.98 $10,442 - $13,193
-3,315 Reduced 73.47%
1,197 $5,000
Q3 2020

Nov 12, 2020

BUY
$3.37 - $3.93 $2,894 - $3,375
859 Added 23.51%
4,512 $17,000
Q2 2020

Jul 31, 2020

BUY
$2.19 - $4.5 $7,608 - $15,633
3,474 Added 1940.78%
3,653 $14,000
Q1 2020

May 01, 2020

BUY
$2.1 - $4.61 $270 - $594
129 Added 258.0%
179 $0
Q4 2019

Feb 14, 2020

BUY
$1.8 - $3.28 $90 - $164
50 New
50 $0

Others Institutions Holding PLX

About Protalix BioTherapeutics, Inc.


  • Ticker PLX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,753,400
  • Market Cap $52.2M
  • Description
  • Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...
More about PLX
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.